FDA Approves BUTORPHANOL TARTRATE — Hikma Pharmaceuticals USA Inc.
Hikma Pharmaceuticals USA Inc. secured FDA approval for its generic nasal butorphanol tartrate product, reinforcing its strategic expansion within the pain management sector. This approval is expected to enhance generic availability and apply competitive pricing pressure to branded analgesic alternatives.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day